The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma

키워드

참고문헌 (42)

1. Lotfi M, "COVID-19 : transmission, prevention, and potential therapeutic opportunities", Clin Chim Acta, 508, pp.254~266 (2020)
2. Shi Y, "An overview of COVID-19", J Zhejiang Univ Sci B, 21, pp.343~360 (2020)
3. 안대균, "Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)", Journal of Microbiology and Biotechnology, 30(3), pp.313~324 (2020), 한국미생물·생명공학회
4. Bakouny Z, "COVID-19 and cancer : current challenges and perspectives", Cancer Cell, 38, pp.629~646 (2020)
5. Liang W, "Cancer patients in SARSCoV-2 infection : a nationwide analysis in China", Lancet Oncol, 21, pp.335~337 (2020)
6. Yang F, "Clinical characteristics and outcomes of cancer patients with COVID-19", J Med Virol, 92, pp.2067~2073 (2020)
7. Yu J, "SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China", JAMA Oncol, 6, pp.1108~1110 (2020)
8. Garassino MC, "COVID-19in patients with thoracic malignancies(TERAVOLT) : first results of an international, registry-based, cohort study", Lancet Oncol, 21, pp.914~922 (2020)
9. Saini KS, "Mortality in patients with cancer and coronavirus disease 2019 : a systematic review and pooled analysis of 52 studies", Eur J Cancer, 139, pp.43~50 (2020)
10. Kuderer NM, "Clinical impact of COVID-19 on patients with cancer(CCC19) : a cohort study", Lancet, 395, pp.1907~1918 (2020)
11. Westblade LF, "SARS-CoV-2viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19", Cancer Cell, 38, pp.661~671 (2020)
12. Williamson EJ, "Factors associated with COVID-19-related death using OpenSAFELY", Nature, 584, pp.430~436 (2020)
13. Vijenthira A, "Outcomes of patients with hematologic malignancies and COVID-19 : a systematic review and meta-analysis of 3377 patients", Blood, 136, pp.2881~2892 (2020)
14. He W, "COVID-19 in persons with haematological cancers", Leukemia, 34, pp.1637~1645 (2020)
15. Cheson BD, "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
16. Kumar S, "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma", Lancet Oncol, 17, pp.e328~e346 (2016)
17. Durie BG, "International uniform response criteria for multiple myeloma", Leukemia, 20, pp.1467~1473 (2006)
18. Baden LR, "Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology", J Natl Compr Canc Netw, 14, pp.882~913 (2016)
19. Tunes da Silva G, "Methods for equivalence and noninferiority testing", Biol Blood Marrow Transplant, 15(1 Suppl), pp.120~127 (2009)
20. Sharman JP, "A randomized, double-blind, efficacy and safety study of PF-05280586(a Rituximab Biosimilar)compared with rituximab reference product(MabThera)in subjects with previously untreated CD20-positive, Low-Tumor-Burden Follicular Lymphoma(LTB-FL)", BioDrugs, 34, pp.171~181 (2020)
21. Jurczak W, "Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma(ASSIST-FL) : primary results from a confirmatory phase 3, double-blind, randomised, controlled study", Lancet Haematol, 4, pp.e350~e361 (2017)
22. Blackwell K, "The global need for a trastuzumab biosimilar for patients with HER2-positive breast cancer", Clin Breast Cancer, 18, pp.95~113 (2018)
23. "Thematic map" (2021)[URL]
24. "Population and population density by region" (2021)[URL]
25. "Population and population density by region" (2021)[URL]
26. "COVID-19 response" (2021)[URL]
27. "COVID-19" (2021)[URL]
28. "Census data" (2020)[URL]
29. Wiersinga WJ, "Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019(COVID-19) : a review", JAMA, 324, pp.782~793 (2020)
30. Shiu EYC, "Controversy around airborne versus droplet transmission of respiratory viruses : implication for infection prevention", Curr Opin Infect Dis, 32, pp.372~379 (2019)
31. Chu DK, "Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19 : a systematic review and meta-analysis", Lancet, 395, pp.1973~1987 (2020)
32. Guner R, "COVID-19 : prevention and control measures in community", Turk J Med Sci, 50(SI-1), pp.571~577 (2020)
33. Hu LQ, "COVID-19 and improved prevention of hospital-acquired infection", Br J Anaesth, 125, pp.e318~e319 (2020)
34. Juang SF, "Integrated hospital quarantine system against COVID-19", Kaohsiung J Med Sci, 36, pp.380~381 (2020)
35. Lee IK, "Effective strategies to prevent coronavirus disease-2019(COVID-19)outbreak in hospital", J Hosp Infect, 105, pp.102~103 (2020)
36. Mizumoto K, "Estimating the asymptomatic proportion of coronavirus disease 2019(COVID-19)cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020", Euro Surveill, 25, pp.2000180~ (2020)
37. Sutton D, "Universal screening for SARS-CoV-2 in women admitted for delivery", N Engl J Med, 382, pp.2163~2164 (2020)
38. Day M, "COVID-19: four fifths of cases are asymptomatic, China figures indicate", BMJ, 369, pp.m1375~ (2020)
39. Bai Y, "Presumed asymptomatic carrier transmission of COVID-19", JAMA, 323, pp.1406~1407 (2020)
40. Rothe C, "Transmission of 2019-nCoV infection from an asymptomatic contact in Germany", N Engl J Med, 382, pp.970~971 (2020)
41. Tong ZD, "Potential presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China, 2020", Emerg Infect Dis, 26, pp.1052~1054 (2020)
42. Ye F, "Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster", Int J Infect Dis, 94, pp.133~138 (2020)

관련 논문AI추천